期刊文献+

携带超抗原SEA基因的白蛋白纳米载体的构建及其治疗膀胱癌潜能研究

Potential of human serum albumin nanoparticles as a novel gene vector to deliver SEA gene for targeting therapy of bladder cancer
原文传递
导出
摘要 目的 构建一种非病毒载体基因投递系统-携带超抗原葡萄球菌肠毒素A(SEA)基因的白蛋白纳米载体,观察白蛋白纳米粒表征并探讨其潜在的靶向基因投递作用和强大的抗瘤机制.方法 采用去溶剂化法制备白蛋白纳米粒,平均粒径(253.1±11.9)nm,Zeta电位(-34.0±4.5)mV,PDI 0.43±0.04;抽提SEA基因质粒(pSEA)260/280:1.84±0.02,pSEA浓度:(85.54±1.43)mg/L;经生物活性及基因测序鉴定后耦合SEA基因质粒和白蛋白纳米载体,并观察耦合物的稳定性及白蛋白纳米载体对SEA基因的保护作用.结果 成功构建携带超抗原SFA基因的白蛋白纳米载体,平均粒径(118.9±4.8)nm,Zeta电位(-43.9±10.5)mV,PDI 0.19±0.02,基因转载率为(97.61±0.06)%,性质稳定、分散性较好,体外实验表明白蛋白纳米载体能保护SEA基因免受DNase Ⅰ的降解.结论 获得符合超抗原SEA基因转染要求的白蛋白纳米载体. Objective To assess the characteristics of human serum albumin nanoparticles (HSA-NP) as a nonviral vector system for delivery staphylococcal enterotoxin A (SEA) gene and probe into its potential targeted antitumor mechanism.Methods HSA-NP and plasmid containing SEA gene (pSEA)encapsulated in HSA (pSEA-HSA-NP) were prepared by a desolvation-crosslinking method.HSA-NP had a mean size of (253.1 ± 11.9) nm,zeta potential of ( -34.0 ±4.5) mV,polydispersity index of 0.43 ±0.04.The superantigen SEA gene was extracted by the Endo-Free Plasmid Maxi Kit,260/280 of pSEA was 1.84 ±0.02 and the concentration of pSEA was ( 85.54 ± 1.43 ) mg/L.pSEA was verified by sequencing and biological activity survey,the stability of pSEA-HSA-NP was investigated by laying for 10 days at room temperature,and the size and zeta potential were remeasured and contrasted with the samples 10 days before.HSA-NP protecting pSEA from degradation of DNase I was detected by gel electrophoresis.Results Electrophoretic mobility analysis and fluorescent labeling revealed that pSEA-HSA-NP was successfully constructed.PSEA-HSA-NP had a mean size of ( 118.9 ±4.8) nm,zeta potential of ( -43.9 ± 10.5 ) mV,polydispersity index of 0.19 ±0.02 and pSEA encapsulation efficiency of (97.61 ±0.06)%.The characteristics of pSEA-HSA-NP solution laying for 10 days at room temperature indicated a better stability and polydispersity.HSA-NP stabilizing pSEA against DNase I in vitro was also testified by gel electrophoresis.Conclusion pPSEA-HSA-NP served the transfecting needs of superantigen SEA gene.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2011年第3期449-451,共3页 Chinese Journal of Experimental Surgery
基金 基金项目:广东省科技计划资助项目(20098060700099)
关键词 超抗原 葡萄球菌肠毒素A 血清白蛋白 纳米粒 基因载体 Superantigen Staphylococcal enterotoxin A Serum albumin Nanoparticles Gene vector
  • 相关文献

参考文献15

  • 1舒晓钢,王国斌.超抗原SEA对人胃癌细胞株小鼠荷瘤模型作用及其机制的研究[J].中华实验外科杂志,2004,21(6):688-689. 被引量:2
  • 2Yu J,Tian R,Xiu B,et al.Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells.Int J Biol Sci,2009,5:135-146.
  • 3Jeudy G,Salvadori F,Chauffert B,et al.Polyethylenimine-mediated in vivo gene transfer of a transmembrane superantigen fusion construct inhibits B16 murine melanoma growth.Cancer Gene Ther,2008,15:742-749.
  • 4Si S,Sun Y,Li Z,et al.Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma.Gene Ther,2006,13:1603-1610.
  • 5Kragh-Hansen U,Chuang VT,Otagiri M.Practical aspects of the ligand-binding and enzymatic properties of human serum albumin.Biol Pharm Bull,2002,25:695-704.
  • 6Mo Y,Barnett ME,Takemoto D,et al.Human serum albumin nanoparticles for efficient delivery of Cu,Zn superoxide dismutase gene.Mol Vis,2007,23:746-757.
  • 7Lu W,Sun Q,Wan J,et al.Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration.Cancer Res,2006,66:11878-11887.
  • 8Davda J,Labhasetwar V.Characterization of nanoparticle uptake by endothelial cells.Int J Pharm,2002,233:51-59.
  • 9Wartlick H,Sp(a)nkuch-Schmitt B,Strebhardt K,et al.Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles.J Control Release,2004,96:483-495.
  • 10Arnedo A,Espuelas S,Irache JM.Albumin nanoparticles as carriers for a phosphodiester oligonucleotide.Int J Pharm,2002,244:59-72.

二级参考文献15

  • 1王焱冰,李轶杰,潘鑫艳,陈蓉,张富春.壳聚糖介导增强DNA疫苗皮肤免疫效果的研究[J].生物技术,2006,16(2):68-71. 被引量:4
  • 2李月涛,霍金龙,信吉阁,曾养志.核酸疫苗的研究及应用进展[J].生物技术通报,2006,22(4):1-5. 被引量:10
  • 3Yuan XY, Yang XR, Cai DN, et al. Intranasal immunization with chitosan/pCETP nanoparticles inhibits atherosclerosis in a rabbit model of atherosclerosis. Vaccine,2008,26 (29 -30) :3727.
  • 4LUSheng-dong(卢圣栋).Experimental Technology of Modem Molecular Biology(现代分子生物学实验技术).第二版(2nd Ed).Beijing(北京):Peking Union Medical College Press(中国协和医科大学出版社),1999.69.
  • 5Barman SP, Lunsford L, Chambers P, et al. Two methods for quantifying DNA extracted from poly ( lactide - co - glycolide ) microspheres. J Controlled Release,2000,69 (3) :337.
  • 6Curotto E, Aros F. Quantitative determination of ehitosan and the percent - age of free amino group. Anal Biochem, 1993,211 (2) : 240.
  • 7Richardson SCW,Kolbe HJV,Duncan R,Potential of low molecular mass chitosan as a DNA delivery system:biocompatibility,body distribution and ability to complex and protect DNA,Int J Pharm,1999,178:231-243.
  • 8Arnedo A,Espuelas S,Irache JM.Albumin namoparticles as carriers for a phosphodiester oligonuckeotide.2002,5:59-72.
  • 9Hainaut P,Hernandez T,Robinson A,et al.IARC Database of p53 gene mutations in human tumors and cell lines:updated compilation,revised formats and new visulisation tools.Nucleic Acids Res,1998,26:205-213.
  • 10ChP(中国药典).2005.VolⅢ(三部):163.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部